![]() The plan called for 22 priority products to be manufactured by a total of 23 manufacturing facilities. Recognizing that more needed to be done, PAVM outlined a continental strategy for building a vaccine-manufacturing ecosystem that could meet the 60% target. And private and public companies committed a total of more than $4 billion.īut the African vaccine-manufacturing industry is still nascent. ![]() African manufacturers forged partnerships with multinational corporations and developing country vaccine manufacturers. Approximately 30 manufacturing projects were announced across 14 countries. In 2021, Gavi, the Vaccine Alliance announced plans to further diversify its supplier base, particularly in Africa. The past 18 months have seen unprecedented global and continental mobilization to improve Africa’s access to COVID-19 vaccines. On the basis of this research, we have identified some of the key actions stakeholders need to take to expand vaccine access on the continent. We also surveyed nine African vaccine-manufacturing companies, modeled economics of African vaccine manufacturers, and analyzed case studies of developing country manufacturers in other parts of the world. We interviewed more than 60 stakeholders, including representatives from continental and global manufacturers, biopharma companies, industry bodies, health organizations, regulatory agencies, and academia. A new report by Wellcome, Biovac, and BCG details vaccine manufacturers’ perspectives on the challenges they face and the areas where they most need support. Ramping up from 1% to 60% is no easy feat. Much remains to be done to fulfill the vision of the Partnerships for African Vaccine Manufacturing (PAVM): that African manufacturers supply 60% of the vaccines needed by the continent by 2040. Yet, despite recent progress, the continent supplies less than 1% of its vaccine doses. The COVID-19 pandemic has made clear the urgent need for greater vaccine-manufacturing capacity and capabilities across the African continent. Stakeholders have a crucial role to play in strengthening manufacturers’ business model, identifying strategic priorities, and identifying short- and long-term strategic priorities.Ī sustainable manufacturing ecosystem will help Africa attain economic viability for its vaccine producers and sufficient vaccine supply for its people.īy Andrew Rodriguez, Mathieu Lamiaux, Emily Serazin, Tolu Oyekan, John Gooch, Jan Gildemeister, and Arthur Salaun.Manufacturers today are not profitable, nor are they clear on which vaccines they should be producing and in what quantity.There has been unprecedented mobilization over the past 18 months to improve African vaccine access to COVID-19 vaccines, but the African manufacturing industry is still nascent.Stakeholder interviews revealed the key challenges that manufacturers face and the areas where they most need support. Technology, Media, and TelecommunicationsĬOVID-19 has highlighted the need for greater vaccine manufacturing capabilities in Africa, which currently produces only 1% of its doses.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |